FDA Approves Blenrep (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

FDA Approves Blenrep (belantamab mafodotin-blmf) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma Print this page London UK 05 August 2020 — GlaxoSmithKline announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) as a monotherapy treatment for adult patients with relapsed or refractory multiple myeloma who have received… Read More »

China spat may be threatening Canada’s bid to get early access to leading COVID-19 vaccine: experts

Article content continued Last month, the company’s co-founder said it was in talks with Russia, Brazil, Chile and Saudi Arabia to conduct Phase 3 trials, which determine whether the vaccine actually protects people against COVID-19 infection. Back in Canada, “we are continuing to wait for the vaccine,” said Scott Halperin, the Dalhousie scientist heading Canada’s… Read More »